For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the introduction of Vyndamax and Attruby represents a genuine breakthrough . These innovative therapies stabilize the transthyretin protein, slowing its harmful build-up and lessening the severity of